Public Release: 

The FASEB Journal: Molecular mechanisms behind AICAr drug; impact on ALL

New study explores the molecular mechanisms behind the drug AICAr and its impact on acute lymphoblastic leukemia

Federation of American Societies for Experimental Biology

AICAr (5-amino-4-imidazolecarboxamide riboside, also called Acadesine) has been found to inhibit cell proliferation and has cytotoxic potential for childhood acute lymphoblastic leukemia (ALL) cells. Much of the drug's cytotoxic mechanisms, however, remain unknown. A new study published in The FASEB Journal explores the mechanisms behind AICAr.

Specifically, the study sought to determine: 1) whether AMP-activated protein kinase (AMPK) was necessary for the cytotoxic effects of AICAr; and 2) if AICAr had selective effects on nucleotide pool balance -- which is critical for cancer cell survival and growth -- in childhood ALL cells. Researchers hypothesized that, just as chemotherapeutic agents cause an imbalance in cellular nucleotide pools that results in slowed tumor growth, AICAr might inhibit ALL cell proliferation by regulating nucleotide metabolism.

Using the CRISPR/Cas9 system, researchers engineered ALL cell lines to study the molecular pathway related to AICAr's cytotoxicity. By knocking out Tumor Protein P53 (TP53) and PRKAA1 (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) in NALM-6 and Reh cell lines, researchers were able to confirm that Acadesine's inhibition of cell proliferation was independent of AMPK activation, but dependent on P53. The researchers then used a liquid chromatography tandem-mass spectrometry system to demonstrate that the drug does indeed generate nucleotide imbalances.

"To our knowledge, this is the first time that the detailed molecular mechanisms of AICAr's cytotoxicity have been carefully characterized in ALL," explained Bin-Bing S. Zhou, PhD, director of the Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine. "With acute lymphoblastic leukemia being the most common form of childhood leukemia, it is our hope that clinical application of AICAr might one day lead to improved cancer therapy."

"Oncologists treating ALL have had this drug on their radar screen for some time and this study advances its mode of action, key to the realization of its full clinical potential," said Thoru Pederson, PhD, Editor-in-Chief of The FASEB Journal.

###

This research was supported by grants from the National Basic Research Program of China, the National Natural Science Foundation of China, and the Science and Technology Commission of Shanghai Municipality.

The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). The world's most cited biology journal according to the Institute for Scientific Information, it has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century. Receive monthly highlights for The FASEB Journal; subscribe at http://www.faseb.org/fjupdate.aspx.

FASEB is composed of 29 societies with more than 130,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and well-being by promoting research and education in biological and biomedical sciences through collaborative advocacy and service to our societies and their members.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.